SOURCE: Paragon Financial Limited

Paragon Financial Limited

February 07, 2012 08:20 ET

Biotechnology Industry Starts Strong in 2012 -- MannKind and Celsion Look to Rally

The Paragon Report Provides Equity Research on MannKind & Celsion

NEW YORK, NY--(Marketwire - Feb 7, 2012) - Biotech stocks are on fire in 2012. The iShares NASDAQ Biotechnology index is up more than 15 percent year-to-date as impressive earnings results have boosted investor optimism in the industry. According to BB Biotech, "neither the government debt crisis nor recessionary pressures nor all the turmoil on the currency front" have been able to slow the biotech sector. The Paragon Report examines investing opportunities in the Biotechnology Industry and provides equity research on MannKind Corporation (NASDAQ: MNKD) and Celsion Corporation (NASDAQ: CLSN). Access to the full company reports can be found at:

www.paragonreport.com/MNKD
www.paragonreport.com/CLSN

BB Biotech says that the expected news flow from biotech pipelines in 2012 "also bodes well" for the industry in the current year. In 2011, regulators approved 13 new biotech products and major R&D milestones were reached all while the industry's revenues and profits exceeded market expectations, BB observes.

Global Industry Analysts, Inc. (GIA) says that improving economic conditions have led to an increase in funding for the biotechnology industry. GIA predicts that the global market for biotechnology will surpass $320 billion by 2015 thanks to increased availability of funding for R&D.

The Paragon Report provides investors with an excellent first step in their due diligence by providing daily trading ideas, and consolidating the public information available on them. For more investment research on the biotechnology industry register with us free at www.paragonreport.com and get exclusive access to our numerous stock reports and industry newsletters.

MannKind Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic products for diabetes and cancer in the United States, Europe, and Asia. Shares of the company slid to new 52-week lows last week after the company announced that it has entered into a purchase agreement with The Mann Group LLC, an entity controlled by MannKind's CEO and principal stockholder, Alfred E. Mann, for the sale of shares of its common stock to The Mann Group.

Celsion Corporation, an oncology drug development company, develops and commercializes targeted chemotherapeutic oncology drugs based on its proprietary heat-activated liposomal technology.

The Paragon Report has not been compensated by any of the above-mentioned publicly traded companies. Paragon Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at http://www.paragonreport.com/disclaimer